EN DE
Watch Stemsation International Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Stemsation International Inc (STSN) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Stemsation International Inc stock $0.01, price $0.01, upside +18.5%, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US85859E1029

SI Stemsation International Inc logo Thin data Nov 11, 2026

Stemsation International Inc

STSN · US

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Even on cautious assumptions the value is 16% above the price ($0.0112). 
Fair value $0.0115 · Fairly valued 
Quality 40/100 
Mixed Growth (revenue YoY +6608.1 %/yr in USD) 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 21/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Stemsation International Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0685 $0.0024 Fair Value $0.0115 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.0024 – $0.0685 · fair‑value band $0.0112 – $0.0118 · the $0.0097 price screens below the $0.0115 fair value. As of Nov 11, 2026.

Follow Stemsation International in your weekly email

Every Wednesday you see whether Stemsation International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Stemsation International, Inc. researches, develops, manufactures, and sells canned and flavored oxygen products in the United States. The company sells its products through business to business and direct to consumers channels.

Show moreShow less

Stemsation International, Inc. was incorporated in 2006 and is headquartered in Plantation, Florida.

Stock analysis

Stemsation International Inc (STSN) currently trades at $0.0097, while our estimate is $0.0115, so the stock looks roughly fairly valued today (gap 15.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0112 (bear) to $0.0118 (bull), the price of $0.0097 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Stemsation International Inc reported revenue of $217K in FY2020 versus $3.4K in FY2010, a compound +51.6%/yr. Reported net income was −$464K in FY2025.

Key figures

Market cap $9.2M Micro · Return on assets (EBIT) −99.1% (5-year average) · Free cash flow −$356K · Net debt $1.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 304% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 19%, STSN screens cheaper than that median.

Fair Value

Bear $0.0112 Fair Value $0.0115 Bull $0.0118
Price $0.0097 · Upside +18.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 32
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6,608.1%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.6%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch STSN, get fair value alerts →

Compare Stemsation International Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +18.6% · Above median
Profitability
Return on assets −3.6% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.84× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)58 · sector 17
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs STSN
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs STSN
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs STSN
Haleon plc HLN $9.17 $8.47 −8% vs STSN
Merck KGaA MRK €149.60 €108.83 −27% vs STSN
Galderma Group GALD CHF 191.40 CHF 112.30 −41% vs STSN
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs STSN
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs STSN
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs STSN
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs STSN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Stemsation International Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Stemsation International Inc Fair Value". https://www.fairvalue-calculator.com/stock/STSN

Frequently asked questions

Is Stemsation International Inc (STSN) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $0.0115 versus a price of $0.0097, about +19% upside (fairly valued).
What is the fair value of STSN?
Our estimate for Stemsation International Inc is $0.0115 (as of Nov 11, 2026), built from audited fundamentals. The current price: $0.0097.
What is the quality score of STSN?
Stemsation International Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stemsation International Inc (STSN)?
Our calculated price target is the estimate of $0.0115 (as of Nov 11, 2026). Cautious scenario $0.0112, optimistic scenario $0.0118. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Stemsation International Inc stock forecast for 2026?
Our estimate puts fair value at $0.0115, about +19% upside versus a price of $0.0097 (fairly valued). Cautious scenario $0.0112, optimistic scenario $0.0118. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Stemsation International Inc (STSN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stemsation International Inc it is $0.0115 per share (as of Nov 11, 2026), against a price of $0.0097.
Is Stemsation International Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, STSN trades below its calculated fair value: price $0.0097, fair value $0.0115, a gap of about +19% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STSN?
No. The price is what the market pays today ($0.0097); the fair value is what the company's own numbers justify ($0.0115). For Stemsation International Inc the two are $0.0018 per share apart. That gap is exactly why we show both numbers side by side.
How much is Stemsation International Inc worth?
The market values Stemsation International Inc at about $9.2M (market capitalisation, as of Nov 11, 2026). Per share that is $0.0097; our models calculate a fair value of $0.0115 per share.
What do the bullish and bearish scenarios say about STSN?
Our models span a range for Stemsation International Inc: cautious scenario $0.0112, base $0.0115, optimistic $0.0118 per share (as of Nov 11, 2026, price $0.0097). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is STSN from its 52-week high?
Stemsation International Inc trades at $0.0097, about 53% below its 52-week high of $0.0205 and 304% above the low of $0.0024 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0115 is for.
Which stocks are comparable to Stemsation International Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stemsation International Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $0.0097, calculated fair value $0.0115 (+19%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Stemsation International Inc currently trades 16% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stemsation International Inc (STSN)?
The closing price on Nov 13, 2026 was $0.0097. Our estimate is $0.0115, about +19% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stemsation International Inc right now?
The price is below even our cautious bear case ($0.0112). The market is more pessimistic than our downside scenario. The models converge in a tight band ($0.0112 to $0.0118), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Stemsation International Inc

How large is the market capitalisation of Stemsation International Inc (STSN)?
The market capitalisation of Stemsation International Inc is $9.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the EBIT return on assets of Stemsation International Inc (STSN)?
On an EBIT basis the return on assets of Stemsation International Inc is −99.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Stemsation International Inc (STSN) generate?
The free cash flow of Stemsation International Inc is −$356K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Stemsation International Inc (STSN) carry?
The net debt of Stemsation International Inc is $1.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Stemsation International Inc in the live analysis

One click puts Stemsation International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.